BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Valens Pharma Ltd. Reports Top-line Results from Voluntary Phase II Trial


7/28/2008 2:43:50 PM

EDMONTON, July 28 /CNW/ - Valens Pharma Ltd. (Valens, formerly known as "CardioMetabolics Inc."), today announced preliminary results from its voluntary Phase II "Mini-Metr(*)ics" clinical trial evaluating its proprietary intravenous formulation of dichloroacetate (DCA i.v.) in high risk, geriatric patients undergoing open heart surgical procedures. A primary objective of this exploratory Phase II study was to collect key information to help design further trials. A secondary objective was to determine if there was evidence of clinical efficacy for endpoints that included reduced time in the Intensive Care Unit for this patient group. Evidence of efficacy for those endpoints was not revealed in this pilot study. However, as expected, the biochemical benefits of DCA shown in earlier trials, such as lower plasma lactate levels and lower, more stable levels of glucose, were confirmed among treated patients.

Read at Canada NewsWire

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES